COVID-19 Drugs

Internal standards for therapeutic drug monitoring of potential COVID-19 drugs

Many laboratories and hospitals around the world are carrying out studies to find a solution against the spread of COVID-19 virus. Several drugs are on the test bench such as Hydroxychloroquine, Favipiravir or Remdesivir. Used alone or in combination with other drugs, these molecules demonstrate promising results. In order to develop and set up dosage methods, e.g. to determine the optimal doses, clinical studies based on therapeutic drug monitoring by LC-MS will be needed.

An Europe-wide clinical trial, called "Discovery", was launched to test four experimental treatments for COVID-19, including the following compounds: Remdesivir, Lopinavir and Ritonavir, Hydroxychloroquine. This trial will also complement the data that will be collected during another international clinical trial, called "Solidarity". Shimadzu and Alsachim are supporting these clinical trials by providing internal standards for therapeutic drug monitoring of these potential anti-COVID-19 drugs.